肿瘤药学Issue(5)：383-388,6.DOI:10.3969/j.issn.2095-1264.2014.079
复方苦参注射液联合腹腔内化疗治疗恶性腹水的Meta分析
Compound Kushen Injection plus Intraperitoneal Chemotherapy in the Treatment of Malignant Ascites:a Meta-analysis
摘要
Abstract
Objective To evaluate the efficacy and safety of compound Kushen injection plus intraperitoneal chemo-therapy for patients with malignant ascites. Methods Databases of CNKI, Wanfang, VIP, CBM and PUBMED were searched and the randomized controlled trials (RCTs) on compound Kushen injection plus intraperitoneal chemotherapy for malignant ascites were included. The quality of included studies was assessed by Jadad scoring. Quantitative data synthesis was con-ducted by using the statistical software Stata 12.0. Results Nine RCTs were included in the present meta-analyses. The in-cluded studies were in low quality. Meta-analysis showed that compound Kushen injection plus intraperitoneal chemother-apy could significantly increase the effective rate (RR=1.555, 95%CI 1.377~1.756), improve the quality of life (RR=1.574, 95%CI 1.352~1.833), and decrease the gastrointestinal reactions (RR=0.728, 95%CI 0.559~0.948), as compared with intraperitoneal chemotherapy alone in the treatment of malignant ascites. Conclusion The present meta-analysis indicated that compound Kushen injection plus intraperitoneal chemotherapy could improve the efficacy and quality of life of patients with malignant ascites. More normalized randomized controlled trials were still needed to provide further evidences.关键词
复方苦参注射液/恶性腹水/腹腔内化疗/随机对照试验/Meta分析Key words
Compound Kushen injection/Malignant ascites/Intraperitoneal chemotherapy/Randomized controlled trial/Meta-analysis分类
医药卫生引用本文复制引用
许钟,曹辉,黄国美,蒋莹..复方苦参注射液联合腹腔内化疗治疗恶性腹水的Meta分析[J].肿瘤药学,2014,(5):383-388,6.基金项目
贵州省科学技术基金博士基金资助项目（黔科合J字2012-2240号）。 （）
